Retatrutide 30mg

A high-purity, lyophilized formulation of Retatrutide (LY3437943) — a novel, long-acting triple agonist of the GLP-1, GIP, and glucagon receptors, designed exclusively for research and analytical use. This next-generation incretin mimetic is under investigation for its profound effects on energy expenditure, glycemic regulation, and adipose metabolism, making it an advanced model compound for metabolic and endocrine studies.

Its extended half-life and broad receptor activation profile make Retatrutide ideal for research requiring sustained metabolic modulation and multi-pathway receptor engagement.

Triple receptor activation:
Simultaneously targets GLP-1, GIP, and glucagon receptors, providing a unique framework for studying coordinated metabolic signaling across pancreatic, hepatic, and adipose tissues.

Profound metabolic effects:
In preclinical and early human models, Retatrutide has demonstrated potent effects on body weight reduction, glucose control, and lipid metabolism, exceeding single- or dual-agonist compounds.

Extended duration of action:
Engineered for once-weekly administration in clinical studies, with a long-acting backbone that maintains stable receptor engagement and consistent exposure profiles.

Ideal for obesity, diabetes, and metabolic syndrome models:
Supports diverse investigations into insulin sensitivity, hepatic fat oxidation, energy expenditure, and neuroendocrine appetite regulation.

High stability and purity:
Manufactured to the highest analytical standards, ensuring reproducibility and precision in laboratory and pharmacodynamic research.

Our Retatrutide 30 mg formulation delivers pharmaceutical-grade quality with verified sequence fidelity and purity — trusted by research teams exploring next-generation metabolic therapeutics.

• ≥99% purity verified via HPLC & Mass Spectrometry

• Synthetic peptide (GLP-1/GIP/Glucagon receptor agonist) validated for structural integrity

• Lyophilized sterile powder for extended shelf stability

• Full COA (Certificate of Analysis) available upon request

• Discreet, tracked shipping and laboratory-grade packaging

Retatrutide acts as a unified incretin and glucagon receptor agonist, simultaneously activating:

• GLP-1R (glucagon-like peptide-1 receptor): enhances insulin secretion, delays gastric emptying, and reduces appetite.

• GIPR (glucose-dependent insulinotropic polypeptide receptor): modulates glucose and lipid metabolism while synergizing with GLP-1 pathways.

• GCGR (glucagon receptor): increases hepatic fat oxidation and energy expenditure.

Through this triple-agonist profile, Retatrutide produces a balanced anabolic-catabolic modulation, allowing researchers to examine:

• Glucose tolerance and beta-cell preservation models

• Adipose metabolism and lipolysis pathways

• Energy expenditure and mitochondrial activity studies

• Hepatic steatosis and NASH models

• Appetite suppression and CNS metabolic signaling

Its distinct pharmacokinetic signature — with an extended half-life and minimal peak-trough fluctuation — makes it ideal for sustained exposure protocols in long-term metabolic studies.

Is Retatrutide legal to purchase?
A: Our Retatrutide is sold strictly as a research chemical, not for human consumption. Researchers must ensure compliance with local and institutional regulations.

How should it be reconstituted for research use?
A: Reconstitute with sterile bacteriostatic water to achieve the desired concentration. Store refrigerated (2–8 °C) after reconstitution. Do not freeze once mixed.

How is Retatrutide different from Tirzepatide (Mounjaro)?
A: While Tirzepatide is a dual GLP-1/GIP receptor agonist, Retatrutide adds glucagon receptor agonism, resulting in enhanced fat oxidation and thermogenic activity in metabolic models.

What makes Retatrutide valuable for research?
A: Its unique triple-receptor profile provides insights into integrated incretin signaling and the balance between anabolic and catabolic metabolic forces, a key area of next-generation obesity and diabetes research.

What are the typical effects observed in preclinical models?
A: Enhanced glucose clearance, significant fat mass reduction, increased energy expenditure, and improved liver lipid metabolism have all been reported in animal models.

What if discoloration or aggregation appears in the vial?
A: Minor clumping may occur and will dissolve upon reconstitution. If severe discoloration or particulate matter is observed, do not use.

Are there known limitations in current literature?
A: As a late-stage experimental compound, human data remain limited, and ongoing research continues to define its receptor selectivity, CNS penetration, and long-term metabolic effects.

Please check your email after purchase for detailed handling guidelines, peptide stability data, and reference literature for metabolic and incretin research applications.